<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136366</url>
  </required_header>
  <id_info>
    <org_study_id>ADX-2191-PVR-001</org_study_id>
    <nct_id>NCT04136366</nct_id>
  </id_info>
  <brief_title>The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy</brief_title>
  <official_title>The GUARD Trial - Part 1: A Phase 3 Clinical Trial of Repeated Intravitreal Injections of ADX-2191 Versus Standard-of-Care for Prevention of Proliferaivie Vitreoretinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldeyra Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aldeyra Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of
      repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of
      proliferative vitreoretinopathy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent retinal detachment</measure>
    <time_frame>Efficacy assessment period (Week 1 to Week 24)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best-corrected visual acuity (BCVA) change from baseline</measure>
    <time_frame>Efficacy assessment period (Week 1 to Week 24)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Proliferative Vitreoretinopathy</condition>
  <arm_group>
    <arm_group_label>ADX-2191 (intravitreal methotrexate 0.8%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADX-2191 (intravitreal methotrexate 0.8%) administered over 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard surgical care procedure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard procedure performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADX-2191 (intravitreal methotrexate 0.8%)</intervention_name>
    <description>ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy</description>
    <arm_group_label>ADX-2191 (intravitreal methotrexate 0.8%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard surgical care procedure</intervention_name>
    <description>Standard surgical care performed upon completion of pars plana vitrectomy</description>
    <arm_group_label>Standard surgical care procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is 18 years or older of any gender or race

          2. Subject is undergoing pars plana vitrectomy due to recurrent retinal detachment due to
             proliferative vitreoretionapthy or open globe injury

          3. Subject is willing and able to provide written informed consent, comply with clinical
             trial procedures, and return for all clinical trial visits

          4. Subjects of childbearing potential must agree to use two forms of birth control for
             the duration of the clinical trial

        Exclusion Criteria:

          1. History of severe non-proliferative or proliferative diabetic retinopathy

          2. Other planned eye surgery during the course of the trial

          3. Participation in a clinical trial with an investigational medicinal product or
             investigational device within 90 days of subject enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bill Cavanagh</last_name>
    <phone>781-257-3063</phone>
    <email>bcavanagh@aldeyra.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Retinal Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Y. Kunimoto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara McCannel, MD</last_name>
      <phone>310-206-7484</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Retina Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S.K. Steven Houston III, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Retina Associates</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Pollack, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Liang, MD</last_name>
      <phone>617-636-5000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey S. Heier, MD</last_name>
      <phone>800-635-0489</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New England Retina Consultants</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Lally, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Associated Retinal Consultants</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamer Mahmoud, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vitreo-Retinal Surgery</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Mittra, MD</last_name>
      <phone>952-929-1311</phone>
    </contact>
    <contact_backup>
      <last_name>Neal Oestreich</last_name>
      <phone>952-259-6262</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Ophthalmology</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Lezzi Jr., MD</last_name>
      <phone>507-284-2744</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Retina Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Blinder, MD</last_name>
      <phone>314-367-1181</phone>
    </contact>
    <contact_backup>
      <last_name>Pam Bilyeu</last_name>
      <phone>314-367-1181</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Long Island VitreoRetinal Consultants</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>11375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan M. Romero, MD</last_name>
      <phone>718-793-6430</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke Health Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lejla Vajzovic, MD</last_name>
      <phone>919-681-3937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Wykoff, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yewlin Chee, MD</last_name>
      <phone>206-744-2020</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADX-2191</keyword>
  <keyword>recurrent retinal detachment</keyword>
  <keyword>open globe injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitreoretinopathy, Proliferative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

